Serivan 17 Tablet contains Pimavanserin Tartrate INN equivalent to Pimavanserin 17 mg. It is manufactured by Incepta Pharmaceuticals Ltd.

Indications: Serivan is indicated for the treatment of hallucinations and delusions associated with psychosis caused by Parkinson's disease.

Pharmacology:The mechanism of action of pimavanserin in the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis is unknown. However, the effect of pimavanserin could be mediated through a combination of inverse agonist and antagonist activity at serotonin 5-HT₂A receptors and to a lesser extent at serotonin 5-HT₂C receptors.  

Dosage and Administration:The recommended dose of Pimavanserin is 34 mg, taken orally as two 17 mg strength tablets once daily, without titration. Serivan can be taken with or without food.  

Side Effects: Common side effects may include:

• Nausea
• Constipation
• Peripheral edema (swelling in arms or legs)
• Gait disturbance (problems with walking)
• Hallucination
• Confusional state

Precautions & Warnings: 

Increased Mortality in Elderly Patients with Dementia-Related Psychosis:Antipsychotic drugs increase the all-cause risk of death in elderly patients with dementia-related psychosis.Serivan is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson’s disease psychosis.  

QT Interval Prolongation:Serivan prolongs the QT interval. The use of Serivan should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval, including certain antiarrhythmics and antipsychotics. It should also be avoided in patients with a history of cardiac arrhythmias, symptomatic bradycardia, hypokalemia or hypomagnesemia, and congenital prolongation of the QT interval.  

Contraindications: Serivan is contraindicated in patients with a history of hypersensitivity reaction to pimavanserin or any of its components.

Drug Interactions:

• Strong CYP3A4 inhibitors (e.g., ketoconazole): Reduce Serivan dose to 17 mg once daily.
• Strong CYP3A4 inducers: May reduce Serivan exposure; monitor for decreased efficacy and consider dose adjustment.

Pregnancy & Lactation: There are no adequate data on pimavanserin use in pregnant women. There is no information regarding the presence of pimavanserin in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Serivan.  

Storage: Store at 20°C to 25°C. Keep out of reach of children.

Important Note: This information is for general knowledge and informational purposes only and does not substitute professional medical advice. Always consult your doctor or pharmacist for specific instructions and guidance regarding your medication. They can assess your individual medical condition and provide the most appropriate advice.